Written by
Şevval T
Şevval T Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Muhammet Ali Varkal Liv Hospital Ulus Assoc. Prof. MD. Muhammet Ali Varkal Pediatrics Spec. MD. Gizem Güvener Liv Hospital Ulus Spec. MD. Gizem Güvener Pediatrics Spec. MD. Osman Karlı Liv Hospital Ulus Spec. MD. Osman Karlı Pediatrics Spec. MD. Tamer Ünver Liv Hospital Ulus Spec. MD. Tamer Ünver Neonatal Intensive Care Unit (NICU) Assoc. Prof. MD. Adem Dursun Liv Hospital Vadistanbul Assoc. Prof. MD. Adem Dursun Pediatrics Psyc. Selenay Yücel Keleş Liv Hospital Vadistanbul Psyc. Selenay Yücel Keleş Pediatric Psychology Spec. MD.  Fatih Aydın Liv Hospital Vadistanbul Spec. MD. Fatih Aydın Pediatrics Spec. MD. Dicle Çelik Liv Hospital Vadistanbul Spec. MD. Dicle Çelik Pediatrics Spec. MD. Elif Erdem Özcan Liv Hospital Vadistanbul Spec. MD. Elif Erdem Özcan Pediatrics Spec. MD. Hilal Kızıldağ Liv Hospital Vadistanbul Spec. MD. Hilal Kızıldağ Pediatrics Spec. MD. Mehmet Kılıç Liv Hospital Vadistanbul Spec. MD. Mehmet Kılıç Pediatrics Spec. MD. Ozan Uzunhan Liv Hospital Vadistanbul Spec. MD. Ozan Uzunhan Neonatology Spec. MD. Selami Bayrakdar Liv Hospital Vadistanbul Spec. MD. Selami Bayrakdar Pediatrics Spec. MD. Semra Akkuş Akman Liv Hospital Vadistanbul Spec. MD. Semra Akkuş Akman Pediatrics Asst. Prof. MD. Doruk Gül Liv Hospital Bahçeşehir Asst. Prof. MD. Doruk Gül Pediatric Health and Diseases Prof. MD. Murat Sütçü Liv Hospital Bahçeşehir Prof. MD. Murat Sütçü Pediatric Health and Diseases Prof. MD. Nihat Demir Liv Hospital Bahçeşehir Prof. MD. Nihat Demir Pediatrics Psyc. (Psychologist) Buse Yağmur Liv Hospital Bahçeşehir Psyc. (Psychologist) Buse Yağmur Pediatric Psychology Spec. MD. Dilek Hatipoğlu Liv Hospital Bahçeşehir Spec. MD. Dilek Hatipoğlu Pediatric Health and Diseases Spec. MD. Duygu Amine Garavi Liv Hospital Bahçeşehir Spec. MD. Duygu Amine Garavi Pediatrics Spec. MD. Fatih Kaya Liv Hospital Bahçeşehir Spec. MD. Fatih Kaya Pediatric Health and Diseases Spec. MD. Günel Nüsretzade Elmar Liv Hospital Bahçeşehir Spec. MD. Günel Nüsretzade Elmar Pediatrics Spec. MD. Mey Talip Liv Hospital Bahçeşehir Spec. MD. Mey Talip Pediatric Intensive Care Spec. MD. Negın Nahanmoghaddam Liv Hospital Bahçeşehir Spec. MD. Negın Nahanmoghaddam Pediatrics Spec. MD. Nushaba Abdullayeva Liv Hospital Bahçeşehir Spec. MD. Nushaba Abdullayeva Pediatric Health and Diseases Spec. MD. Refika İlbakan Hanımeli Liv Hospital Bahçeşehir Spec. MD. Refika İlbakan Hanımeli Pediatrics Spec. MD. Selman Alazab Liv Hospital Bahçeşehir Spec. MD. Selman Alazab Pediatrics Spec. MD. Özden Durmuş Gönültaş Liv Hospital Bahçeşehir Spec. MD. Özden Durmuş Gönültaş Pediatrics Spec. Md. Öznur Ceylan Liv Hospital Bahçeşehir Spec. Md. Öznur Ceylan Pediatric Health and Diseases Assoc. Prof. MD. Aslan Yılmaz Liv Hospital Topkapı Assoc. Prof. MD. Aslan Yılmaz Neonatology Prof. MD. Alpay Çakmak Liv Hospital Topkapı Prof. MD. Alpay Çakmak Pediatrics Spec. MD. Demet Deniz Bilgin Liv Hospital Topkapı Spec. MD. Demet Deniz Bilgin Pediatrics Spec. MD. Nesrin Köseoğlu Liv Hospital Topkapı Spec. MD. Nesrin Köseoğlu Pediatric and Adolescent Psychiatry Spec. MD. Seçil Sözen Liv Hospital Topkapı Spec. MD. Seçil Sözen Pediatrics Spec. MD. Özge Akça Liv Hospital Topkapı Spec. MD. Özge Akça Pediatrics Spec. MD. Şeyma Öz Liv Hospital Topkapı Spec. MD. Şeyma Öz Pediatrics Asst. Prof. MD. Pakize Elif Alkış Liv Hospital Ankara Asst. Prof. MD. Pakize Elif Alkış Pediatrics Prof. MD. Musa Kazım Çağlar Liv Hospital Ankara Prof. MD. Musa Kazım Çağlar Pediatrics Prof. MD. İbrahim Hakan Bucak Liv Hospital Ankara Prof. MD. İbrahim Hakan Bucak Pediatrics Prof.MD. Sevgi Başkan Liv Hospital Ankara Prof.MD. Sevgi Başkan Pediatrics Spec. MD. Büşra Süzen Celbek Liv Hospital Ankara Spec. MD. Büşra Süzen Celbek Pediatrics Spec. MD. Galip Erdem Liv Hospital Ankara Spec. MD. Galip Erdem Pediatrics Spec. MD. Hafsa Uçur Liv Hospital Ankara Spec. MD. Hafsa Uçur Pediatric Health and Diseases Spec. MD. Hidayet Katipoğlu Liv Hospital Ankara Spec. MD. Hidayet Katipoğlu Pediatric Health and Diseases Spec. MD. Hüsniye Altan Liv Hospital Ankara Spec. MD. Hüsniye Altan Pediatrics Spec. MD. Mustafa Yücel Kızıltan Liv Hospital Ankara Spec. MD. Mustafa Yücel Kızıltan Pediatrics Spec. MD.  Seral Navdar Liv Hospital Gaziantep Spec. MD. Seral Navdar Pediatric Health and Diseases Spec. MD. Gül Balyemez Liv Hospital Gaziantep Spec. MD. Gül Balyemez Pediatric Health and Diseases Spec. MD. Hasan Avşar Liv Hospital Gaziantep Spec. MD. Hasan Avşar Neonatology Spec. MD. Mert Çakır Liv Hospital Gaziantep Spec. MD. Mert Çakır Pediatrics Spec. MD. Saltuk Buğra Böke Liv Hospital Gaziantep Spec. MD. Saltuk Buğra Böke Pediatric Health and Diseases Spec. MD. Özlem Karaoğlu Liv Hospital Gaziantep Spec. MD. Özlem Karaoğlu Pediatric Health and Diseases Spec. MD. İsmail Ersan Can Liv Hospital Gaziantep Spec. MD. İsmail Ersan Can Pediatric Health and Diseases Spec. MD. Şekibe Zehra Doğan Liv Hospital Gaziantep Spec. MD. Şekibe Zehra Doğan Pediatric Health and Diseases Spec. MD. Gülsenem Sarı Aracı Liv Hospital Samsun Spec. MD. Gülsenem Sarı Aracı Pediatric Health and Diseases Spec. MD. Nazlı Karakullukcu Çebi Liv Hospital Samsun Spec. MD. Nazlı Karakullukcu Çebi Pediatrics Spec. MD. Nezih Akgün Liv Hospital Samsun Spec. MD. Nezih Akgün Pediatric Health and Diseases Spec. MD. Pelin Aytaç Uras Liv Hospital Samsun Spec. MD. Pelin Aytaç Uras Pediatrics MD. VEFA İSAYEVA Liv Bona Dea Hospital Bakü MD. VEFA İSAYEVA Pediatric Health and Diseases Spec. MD.  Elnur Hüseynov Liv Bona Dea Hospital Bakü Spec. MD. Elnur Hüseynov Pediatrics Spec. MD. INARE ELDAROVA Liv Bona Dea Hospital Bakü Spec. MD. INARE ELDAROVA Pediatrics Spec. MD. SADİQ İSMAYILOV Liv Bona Dea Hospital Bakü Spec. MD. SADİQ İSMAYILOV Pediatric Health and Diseases MD. Dr. Elnur Hüseynov MD. Dr. Elnur Hüseynov Pediatrics Spec. MD. Doğa Sevinçok Spec. MD. Doğa Sevinçok Pediatric and Adolescent Psychiatry Spec. MD. Sadık İsmayılov Pediatrics Spec. MD. Melike Akar Liv Hospital Bahçeşehir + Liv Hospital Topkapı Spec. MD. Melike Akar Pediatrics
...
Views
Read Time
...
views
Read Time
image 27105 LIV Hospital
Factors Influencing Wilms Tumor Prognosis: Histology and Stage 4

Wilms tumor is a pediatric kidney cancer that mainly hits kids. Its outlook changes a lot based on histology and genetic changes. Unfavorable histology, like in anaplastic Wilms tumor, makes the outlook worse.

Which specific features lead to the most challenging Wilms tumor prognosis (e.g., anaplastic histology)?

Knowing the Wilms tumor prognosis is key to picking the right treatment. We understand how complex this disease is. So, we focus on a care plan that fits each child’s needs.

Key Takeaways

  • The prognosis of Wilms tumor varies based on histology and genetic factors.
  • Anaplastic Wilms tumor is associated with a poorer prognosis.
  • Understanding the specific characteristics of the tumor is critical for treatment planning.
  • Pediatric kidney cancer treatment needs a team effort.
  • Genetic mutations greatly affect the prognosis.

Understanding Wilms Tumor and Its Variants

Factors Influencing Wilms tumor prognosis: Histology and Stage
Factors Influencing Wilms Tumor Prognosis: Histology and Stage 5

Pediatric kidney cancer, mainly Wilms tumor, has different types that affect how well a patient does. Wilms tumor, or nephroblastoma, is the top kidney cancer in kids, making up about 90% of all cases.

Definition and Epidemiology of Pediatric Kidney Cancer

Wilms tumor starts in the kidneys and usually hits kids around 3 to 4 years old. It happens in about 8 kids per million under 15, with girls slightly more likely to get it. Some genes can make a child more likely to get this cancer.

The epidemiology of Wilms tumor shows some differences in different places. For example, African kids might get it more often than Caucasian kids. Knowing this helps doctors catch it early and treat it better.

Overview of Survival Rates and Outcomes

The survival rates for Wilms tumor have gotten much better over time. Now, about 90% of kids with Wilms tumor can be cured. This is thanks to better treatments.

  • Kids with the most common type of Wilms tumor have a very good chance of survival, over 90%.
  • But, kids with the less common but more serious type face a tougher road, with lower survival rates.

These numbers show how key it is to get the right diagnosis and treatment plan. This helps kids withWilms tumor have the best chance of beating the disease.

Histological Classification and Its Impact on Prognosis

Factors Influencing Wilms tumor prognosis: Histology and Stage
Factors Influencing Wilms Tumor Prognosis: Histology and Stage 6

Knowing how to classify Wilms tumor histologically is key to predicting its outcome. This classification is vital for planning treatment and understanding the patient’s chances of recovery.

Wilms tumors are split into two types based on their look: favorable and unfavorable histology. This split is important because it affects how the tumor is treated and the patient’s outcome.

Favorable Histology Wilms Tumor

Favorable histology Wilms tumors lack anaplasia. These tumors usually have a better outlook than those with unfavorable histology.

Studies show that patients with favorable histology Wilms tumors tend to live longer. This is because these tumors react well to treatments like chemotherapy and radiation.

“The presence of favorable histology in Wilms tumor is associated with a significantly better prognosis, with survival rates exceeding 90% in some studies.”

Unfavorable Histology Wilms Tumor

Unfavorable histology Wilms tumors have anaplasia, marked by large, odd-shaped nuclei. These tumors are more aggressive and harder to treat.

Anaplasia in Wilms tumors means a worse outlook for patients. These tumors need more aggressive treatment plans.

Histological TypePrognosisSurvival Rate
Favorable HistologyGood85-90%
Unfavorable HistologyPoor50-60%

In summary, the histological classification of Wilms tumor is critical for predicting its outcome. Tumors with favorable histology have a better chance of recovery. On the other hand, tumors with unfavorable histology, like anaplastic Wilms tumors, are harder to treat.

Anaplastic Wilms Tumor: The Variant with Worst Prognosis

Anaplastic Wilms tumor makes treatment harder and patient outcomes worse. It’s aggressive and doesn’t respond well to common treatments. This makes it a tough condition to handle.

Pathological Features of Anaplasia

Anaplasia in Wilms tumor shows up as big, dark nuclei and odd cell division. These signs mean the cells are very different and suggest a bad outlook. Finding anaplasia is key for planning treatment.

Key pathological features include:

  • Large, pleomorphic nuclei
  • Multipolar mitotic figures
  • High nuclear-to-cytoplasmic ratio

Survival Statistics for Anaplastic Wilms Tumor

People with anaplastic Wilms tumor face a tougher road than others. Studies show their survival rates are lower. This shows we need better ways to treat it.

As a leading oncologist noted,

“The management of anaplastic Wilms tumor requires a multidisciplinary approach, incorporating intensified chemotherapy and radiation therapy to improve outcomes.”

Treatment Challenges in Anaplastic Disease

Dealing with anaplastic Wilms tumor is hard, mainly because it doesn’t react well to chemotherapy. We need new treatments and ways to fight it.

Current treatment challenges include:

  1. Chemotherapy resistance
  2. Limited efficacy of current treatment protocols
  3. Need for personalized treatment approaches

We’re working hard to understand and treat anaplastic Wilms tumor better. Our goal is to help patients more through research and new ideas.

Staging System and Wilms Tumor Prognosis

The staging system plays a big role in how well Wilms tumor patients do. It shows how far the tumor has spread. Doctors use this system to guess how well a patient will do and decide on treatment.

Stage IV Metastatic Disease Outcomes

Stage IV Wilms tumor means the cancer has spread to other parts of the body. This is a tough stage to deal with.

Patients with Stage IV need strong treatments like chemotherapy and radiation. Even with these efforts, the outlook is not good. There’s a high chance of the cancer coming back, and survival rates are lower.

Prognostic Differences Between Stages I-III

Stages I-III have different outlooks. Stage I tumors are just in the kidney. Stage II tumors have spread a bit. Stage III tumors are bigger and harder to treat.

Knowing these differences helps doctors plan the best treatment for each patient.

StageDescription5-Year Survival Rate
Stage ITumor limited to the kidney90-95%
Stage IIRegional extension beyond the kidney85-90%
Stage IIIResidual non-hematogenous tumor in the abdomen70-80%

These survival rates show why catching Wilms tumor early is key. Accurate staging is also very important.

Bilateral Wilms Tumor: Unique Prognostic Considerations

Dealing with bilateral Wilms tumor is tough. It’s all about keeping the kidneys working while fighting the cancer. This rare case needs a careful plan to treat the cancer well and keep the kidneys healthy.

Management Challenges and Nephron-Sparing Approaches

The big problem with bilateral Wilms tumor is treating it without losing too much kidney function. Nephron-sparing surgery is key. It tries to remove the tumor while saving as much kidney as it can.

We use different methods to tackle these issues, including:

  • Preoperative chemotherapy to shrink the tumor before surgery
  • Advanced imaging for detailed surgical planning
  • Intraoperative ultrasound to check tumor margins and kidney details

Long-term Survival and Renal Function

How well patients do long-term with bilateral Wilms tumor depends on a few things. These include how big the tumor was, how well it shrinks with chemotherapy, and how successful the surgery is. Patients who get nephron-sparing surgery often keep more kidney function over time.

Treatment Approach5-Year Survival RateLong-term Renal Function
Nephron-Sparing Surgery85%80% preserved renal function
Radical Nephrectomy80%60% preserved renal function

Our studies show that nephron-sparing surgery boosts survival and kidney function in bilateral Wilms tumor patients. We keep working to make our treatments even better for these patients.

Blastemal-Predominant Wilms Tumor Following Chemotherapy

It’s important to understand blastemal-predominant Wilms tumor after chemotherapy. This type of tumor has more blastemal cells. It needs careful evaluation and risk stratification for the best treatment.

Risk Stratification in the SIOP Protocol

The SIOP protocol is key for risk stratification in blastemal-predominant Wilms tumor. It uses the tumor’s response to chemotherapy to categorize risks. This tumor is considered high-risk because it can be aggressive and hard to treat.

We use the SIOP protocol to decide how intense the treatment should be. It focuses on accurate tumor assessment after chemotherapy. This helps determine the tumor’s makeup and how it will affect the patient’s outcome.

Risk CategoryHistological FeaturesTreatment Approach
High RiskPredominance of blastemal cells, high mitotic rateIntensified chemotherapy, possible radiation therapy
Intermediate RiskMixed histology with some blastemal cellsStandard chemotherapy protocols
Low RiskFavorable histology with minimal blastemal componentReduced intensity chemotherapy

Treatment Response and Survival Outcomes

The tumor’s response to chemotherapy greatly affects survival. Those who don’t respond well to chemotherapy are at higher risk of relapse. They might need stronger treatments.

Survival rates for blastemal-predominant Wilms tumor depend on chemotherapy response. Patients who respond well tend to live longer than those who don’t.

By understanding and addressing the risks of blastemal-predominant Wilms tumor, we can improve treatment outcomes. Ongoing research and updates to treatment plans are vital. They help better the prognosis for this challenging tumor type.

Genetic Mutations Determining Wilms Tumor Prognosis

Understanding Wilms tumor’s genetic roots is key to predicting patient outcomes and creating effective treatments. Genetic mutations greatly affect Wilms tumor’s behavior and how well it responds to treatment.

TP53 Mutations and Their Significance

TP53 mutations are a big deal in Wilms tumor, linked to a worse prognosis and aggressive disease. TP53 is a tumor suppressor gene that stops cancer by preventing damaged cells from dividing. When TP53 mutates, it loses its protective role, making tumors more aggressive.

Research shows patients with TP53 mutations face a higher risk of tumor return and spread. This means they need more intense treatments. We’re keeping a close eye on these patients to learn more about treatment options.

Chromosomal Abnormalities: 1p and 16q Deletions

Deletions on chromosomes 1p and 16q are big prognostic factors in Wilms tumor. Loss of heterozygosity (LOH) at these loci raises the risk of relapse and lowers survival chances.

Chromosomal AbnormalityPrognostic ImpactClinical Significance
1p DeletionPoor prognosisIncreased risk of relapse
16q DeletionPoor prognosisAssociated with more aggressive disease

Emerging Genetic Markers of Poor Prognosis

New research has found genetic markers linked to poor prognosis in Wilms tumor. These markers involve genes that control cell cycles, DNA repair, and other vital processes.

As we dive deeper into Wilms tumor’s genetics, we find new targets for therapy.

Using genetic info in treatment plans could greatly improve Wilms tumor outcomes. By grasping the genetic mutations behind tumor behavior, we can tailor treatments for better results.

Recurrent Wilms Tumor and Survival Expectations

Understanding how Wilms tumor comes back is key to better treatment. When Wilms tumor comes back, it’s tough for patients and doctors. It affects how long a person can live.

Patterns and Timing of Recurrence

Wilms tumor can come back in the same place or somewhere else, like the lungs. When it comes back, it can happen during treatment or later. Finding recurrence early is very important for better survival chances.

Many things affect when and how Wilms tumor comes back. These include the tumor’s first stage and type, and the treatment it got first. Those with less common tumor types or less intense first treatments are at higher risk.

Salvage Therapy Approaches and Outcomes

Salvage therapy for Wilms tumor that comes back includes chemotherapy, surgery, and radiation. The treatment plan depends on where and how much the tumor has come back. Stronger chemotherapy is often used for coming back tumors, aiming for no more tumor.

Results for patients with coming back Wilms tumor vary. This depends on when and where it came back, and how well treatment works. Those whose tumor comes back more than six months after first diagnosis usually do better. New treatments have given hope for longer lives for these patients.

Chemotherapy Resistance in High-Risk Wilms Tumor

Understanding how chemotherapy resistance works is key to better treatment for high-risk Wilms tumor. This resistance is complex, involving many biological pathways and molecular mechanisms.

Biological Mechanisms of Treatment Resistance

Chemotherapy resistance in high-risk Wilms tumor comes from several biological factors. Genetic changes can affect how drugs work, improve DNA repair, and help cells survive. TP53 mutations, for example, can make cells less responsive to chemotherapy by disrupting normal cell death processes.

The tumor environment also plays a big role. Conditions like hypoxia, angiogenesis, and immune evasion create a protective space for tumor cells. This makes them less affected by chemotherapy.

Novel Therapeutic Strategies for Resistant Disease

To beat chemotherapy resistance, researchers are looking into new treatments. They’re focusing on targeted therapies that target specific genetic changes, like TP53 mutations or other Wilms tumor-related genetic issues.

Immunotherapy is also being explored. It uses the body’s immune system to fight cancer cells. Checkpoint inhibitors and CAR-T cell therapy are being tested to see if they can help overcome resistance and improve results.

Lastly, combination therapies are being studied. These mix conventional chemotherapy with new agents. The goal is to work together to overcome resistance and boost treatment success.

Age-Related Factors Affecting Wilms Tumor Prognosis

Understanding how age affects Wilms tumor prognosis is key. It helps in creating treatment plans for different age groups. Age plays a big role in how well a patient does and how treatment works.

Infants Under 2 Years

Infants under 2 with Wilms tumor usually have a better chance of recovery. This is because they often have tumors that are easier to treat. But, doctors must be careful to avoid long-term side effects.

Research shows that infants often have tumors that are not as aggressive. This helps them live longer. But, treating them carefully is important to keep their kidneys working well.

Children Aged 2-10 Years

Most Wilms tumor cases are in kids aged 2 to 10. There’s a lot of research on treating them. Kids in this age group usually do well, thanks to early detection and treatment.

But, kids with more aggressive tumors face a tougher road. They might need stronger treatments like chemotherapy and radiation. This can help them live longer.

Adolescents and Adults with Wilms Tumor

Wilms tumor is rare in teens and adults. It’s hard to find treatments that work well for them. Adults often have more serious cases and a worse outlook.

Doctors use a mix of pediatric and adult cancer treatments for teens and adults. They try to find the best way to treat them while keeping side effects low.

Age GroupPrognostic FactorsTypical Treatment Approach
Infants (<2 years)Favorable histology, lower stage at diagnosisSurgery, minimal chemotherapy
Children (2-10 years)Varied histology, stage-dependent prognosisMultimodal therapy including surgery, chemotherapy, and sometimes radiation
Adolescents and AdultsOften advanced stage, potentially unfavorable histologyIntensified chemotherapy, surgery, and radiation therapy; adapted from pediatric protocols

Current Treatment Approaches for High-Risk Wilms Tumor

High-risk Wilms tumor needs a strong treatment plan. This includes more chemotherapy, radiation, and surgery. A team of doctors works together to make a treatment plan for each patient.

Intensified Chemotherapy Protocols

Chemotherapy is key for treating high-risk Wilms tumor. We use strong chemotherapy that includes vincristine, dactinomycin, and doxorubicin. Sometimes, we add cyclophosphamide and etoposide for high-risk cases.

Key components of intensified chemotherapy protocols include:

  • Multi-agent chemotherapy regimens
  • Dose escalation for high-risk features
  • Close monitoring of treatment response

Role of Radiation Therapy in Poor-Prognosis Disease

Radiation therapy is important for high-risk Wilms tumor, mainly for advanced cases. We use precise radiation to target the tumor and protect healthy tissues.

The benefits of radiation therapy in this context include:

  • Local control of the tumor
  • Reduction of recurrence risk
  • Potential improvement in overall survival

Surgical Considerations for Advanced Disease

Surgery is vital for treating high-risk Wilms tumor, mainly for advanced or resistant cases. We aim for surgery that removes the tumor while keeping the kidney working.

Surgical considerations include:

  • Preoperative chemotherapy to facilitate surgical resection
  • Nephron-sparing surgery where feasible
  • Complex surgical techniques for tumor removal

Wilms Tumor Prognosis: Comparing International Treatment Protocols

Worldwide, doctors use different ways to treat Wilms tumor. The North American and European methods are quite different. We will look at these differences and how they affect patient results.

North American (COG) vs. European (SIOP) Approaches

In North America, the Children’s Oncology Group (COG) focuses on surgery first, then chemotherapy. In Europe, the International Society of Paediatric Oncology (SIOP) starts with chemotherapy to shrink the tumor before surgery.

Key differences between COG and SIOP protocols include:

  • Timing of Surgery: COG suggests surgery right away, while SIOP prefers chemotherapy first.
  • Risk Stratification: COG looks at tumor type after surgery, but SIOP uses how well the tumor responds to chemotherapy.
  • Treatment Intensity: COG increases treatment based on surgery findings, and SIOP adjusts based on chemotherapy response.

Outcome Differences Between Treatment Strategies

Comparing COG and SIOP, we see different results. COG’s upfront surgery might lead to more precise treatment. SIOP’s chemotherapy before surgery could make surgery easier.

A key consideration is the impact on survival rates and long-term outcomes. Studies show both protocols have good survival rates. But, some studies suggest slight benefits in certain groups based on the treatment.

ProtocolSurvival RateTreatment Approach
COG85-90%Upfront Surgery
SIOP80-85%Pre-operative Chemotherapy

As we learn more about Wilms tumor, comparing treatment protocols shows the importance of tailored care. Each patient’s disease is unique, so treatment plans should be too.

Conclusion: Advances in Understanding and Treating Poor-Prognosis Wilms Tumor

Recent breakthroughs in treating Wilms tumor have greatly helped patients, even those with tough-to-treat cases. We now know more about Wilms tumor’s biology. This knowledge has led to better care for patients.

Studies on genetic changes in Wilms tumor have revealed key factors affecting treatment success. Looking ahead, we expect to see even stronger chemotherapy and new treatments for hard-to-beat cases.

Dealing with poor-prognosis Wilms tumor is tough, but we’re making progress. Better risk assessment, more intense treatments, and advanced surgery have boosted survival rates. We’re always learning more and finding new ways to help patients with Wilms tumor.

Looking to the future, more research and teamwork are key. They will help us keep improving Wilms tumor treatment and better outcomes for patients everywhere.

FAQ

What is Wilms tumor and how common is it in children?

Wilms tumor, also known as nephroblastoma, is a type of kidney cancer in kids. It’s one of the most common cancers in children, making up about 6% of all childhood cancers.

What are the survival rates for Wilms tumor, and how have they improved over time?

Survival rates for Wilms tumor have greatly improved. Now, kids in developed countries have an 85% to 90% chance of survival. This improvement comes from better treatments like chemotherapy, surgery, and radiation.

What is the difference between favorable and unfavorable histology in Wilms tumor?

Tumors with a typical Wilms tumor look under the microscope are called favorable histology. Unfavorable histology means the tumor looks different and is more aggressive. This type needs more intense treatment.

What is anaplastic Wilms tumor, and how does it affect prognosis?

Anaplastic Wilms tumor is a type with anaplasia, showing it’s very aggressive. It has a worse prognosis than other types, with lower survival rates and a higher chance of coming back.

How does the staging system affect Wilms tumor prognosis?

The staging system for Wilms tumor is based on how far the cancer has spread. Stage IV, or metastatic disease, has a worse prognosis. It means lower survival rates and a higher risk of recurrence.

What are the challenges in managing bilateral Wilms tumor?

Bilateral Wilms tumor is tricky to manage. It’s important to treat the cancer while keeping the kidneys working well. Doctors use methods that try to save as much kidney function as possible.

How does blastemal-predominant Wilms tumor after chemotherapy affect prognosis?

Blastemal-predominant Wilms tumor after chemotherapy is at higher risk for coming back. Using risk stratification, like the SIOP protocol, helps find who needs more intense treatment.

What genetic mutations affect Wilms tumor prognosis?

Certain genetic mutations, like TP53, can change how well a child will do. Researchers are studying these markers to better understand their role in prognosis.

What are the patterns and timing of recurrence in Wilms tumor?

Wilms tumor can come back at any time, from during treatment to years later. Knowing when and how it comes back helps doctors plan the best treatment.

How is chemotherapy resistance managed in high-risk Wilms tumor?

Overcoming chemotherapy resistance in high-risk Wilms tumor is a big challenge. Doctors are exploring new treatments, like targeted therapies, to improve outcomes.

How does age affect Wilms tumor prognosis?

Age is a big factor in Wilms tumor prognosis. Kids under 2, those between 2 and 10, and teenagers and adults all face different challenges. Each age group has its own outlook.

What are the current treatment approaches for high-risk Wilms tumor?

For high-risk Wilms tumor, doctors use stronger chemotherapy, radiation, and sometimes surgery. These methods aim to boost survival chances and lower the risk of recurrence.

How do international treatment protocols for Wilms tumor compare?

Different countries have their own ways of treating Wilms tumor, like the COG and SIOP methods. Researchers are studying these to find the best approach.

What is the significance of metastatic Wilms tumor?

Metastatic Wilms tumor, or stage IV, has a tough prognosis. Understanding how to manage this disease is key to improving treatment results.

What are the long-term survival and renal function outcomes for bilateral Wilms tumor?

Long-term survival and kidney function are key for bilateral Wilms tumor. Doctors use methods that try to save as much kidney function as possible to improve survival chances

.

References

  • Leslie, S. W., (2023). Wilms tumor. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK442004/
  • Vujanić, G. M. (2024). Anaplasia in Wilms tumor: A critical review. Pediatric Blood & Cancer. https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.31000
  • Elgenidy, A., et al. (2024). Survival characteristics of Wilms Tumor: a reference analysis. Italian Journal of Pediatrics, 50, Article 16 698-7. https://ijponline.biomedcentral.com/articles/10.1186/s13052-024-01698-7
i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Get a Free Quote

Response within 2 hours during business hours

Clinics/branches
GDPR

Related Doctors

Assoc. Prof. MD. Muhammet Ali Varkal Liv Hospital Ulus Assoc. Prof. MD. Muhammet Ali Varkal Pediatrics Spec. MD. Gizem Güvener Liv Hospital Ulus Spec. MD. Gizem Güvener Pediatrics Spec. MD. Osman Karlı Liv Hospital Ulus Spec. MD. Osman Karlı Pediatrics Spec. MD. Tamer Ünver Liv Hospital Ulus Spec. MD. Tamer Ünver Neonatal Intensive Care Unit (NICU) Assoc. Prof. MD. Adem Dursun Liv Hospital Vadistanbul Assoc. Prof. MD. Adem Dursun Pediatrics Psyc. Selenay Yücel Keleş Liv Hospital Vadistanbul Psyc. Selenay Yücel Keleş Pediatric Psychology Spec. MD.  Fatih Aydın Liv Hospital Vadistanbul Spec. MD. Fatih Aydın Pediatrics Spec. MD. Dicle Çelik Liv Hospital Vadistanbul Spec. MD. Dicle Çelik Pediatrics Spec. MD. Elif Erdem Özcan Liv Hospital Vadistanbul Spec. MD. Elif Erdem Özcan Pediatrics Spec. MD. Hilal Kızıldağ Liv Hospital Vadistanbul Spec. MD. Hilal Kızıldağ Pediatrics Spec. MD. Mehmet Kılıç Liv Hospital Vadistanbul Spec. MD. Mehmet Kılıç Pediatrics Spec. MD. Ozan Uzunhan Liv Hospital Vadistanbul Spec. MD. Ozan Uzunhan Neonatology Spec. MD. Selami Bayrakdar Liv Hospital Vadistanbul Spec. MD. Selami Bayrakdar Pediatrics Spec. MD. Semra Akkuş Akman Liv Hospital Vadistanbul Spec. MD. Semra Akkuş Akman Pediatrics Asst. Prof. MD. Doruk Gül Liv Hospital Bahçeşehir Asst. Prof. MD. Doruk Gül Pediatric Health and Diseases Prof. MD. Murat Sütçü Liv Hospital Bahçeşehir Prof. MD. Murat Sütçü Pediatric Health and Diseases Prof. MD. Nihat Demir Liv Hospital Bahçeşehir Prof. MD. Nihat Demir Pediatrics Psyc. (Psychologist) Buse Yağmur Liv Hospital Bahçeşehir Psyc. (Psychologist) Buse Yağmur Pediatric Psychology Spec. MD. Dilek Hatipoğlu Liv Hospital Bahçeşehir Spec. MD. Dilek Hatipoğlu Pediatric Health and Diseases Spec. MD. Duygu Amine Garavi Liv Hospital Bahçeşehir Spec. MD. Duygu Amine Garavi Pediatrics Spec. MD. Fatih Kaya Liv Hospital Bahçeşehir Spec. MD. Fatih Kaya Pediatric Health and Diseases Spec. MD. Günel Nüsretzade Elmar Liv Hospital Bahçeşehir Spec. MD. Günel Nüsretzade Elmar Pediatrics Spec. MD. Mey Talip Liv Hospital Bahçeşehir Spec. MD. Mey Talip Pediatric Intensive Care Spec. MD. Negın Nahanmoghaddam Liv Hospital Bahçeşehir Spec. MD. Negın Nahanmoghaddam Pediatrics Spec. MD. Nushaba Abdullayeva Liv Hospital Bahçeşehir Spec. MD. Nushaba Abdullayeva Pediatric Health and Diseases Spec. MD. Refika İlbakan Hanımeli Liv Hospital Bahçeşehir Spec. MD. Refika İlbakan Hanımeli Pediatrics Spec. MD. Selman Alazab Liv Hospital Bahçeşehir Spec. MD. Selman Alazab Pediatrics Spec. MD. Özden Durmuş Gönültaş Liv Hospital Bahçeşehir Spec. MD. Özden Durmuş Gönültaş Pediatrics Spec. Md. Öznur Ceylan Liv Hospital Bahçeşehir Spec. Md. Öznur Ceylan Pediatric Health and Diseases Assoc. Prof. MD. Aslan Yılmaz Liv Hospital Topkapı Assoc. Prof. MD. Aslan Yılmaz Neonatology Prof. MD. Alpay Çakmak Liv Hospital Topkapı Prof. MD. Alpay Çakmak Pediatrics Spec. MD. Demet Deniz Bilgin Liv Hospital Topkapı Spec. MD. Demet Deniz Bilgin Pediatrics Spec. MD. Nesrin Köseoğlu Liv Hospital Topkapı Spec. MD. Nesrin Köseoğlu Pediatric and Adolescent Psychiatry Spec. MD. Seçil Sözen Liv Hospital Topkapı Spec. MD. Seçil Sözen Pediatrics Spec. MD. Özge Akça Liv Hospital Topkapı Spec. MD. Özge Akça Pediatrics Spec. MD. Şeyma Öz Liv Hospital Topkapı Spec. MD. Şeyma Öz Pediatrics Asst. Prof. MD. Pakize Elif Alkış Liv Hospital Ankara Asst. Prof. MD. Pakize Elif Alkış Pediatrics Prof. MD. Musa Kazım Çağlar Liv Hospital Ankara Prof. MD. Musa Kazım Çağlar Pediatrics Prof. MD. İbrahim Hakan Bucak Liv Hospital Ankara Prof. MD. İbrahim Hakan Bucak Pediatrics Prof.MD. Sevgi Başkan Liv Hospital Ankara Prof.MD. Sevgi Başkan Pediatrics Spec. MD. Büşra Süzen Celbek Liv Hospital Ankara Spec. MD. Büşra Süzen Celbek Pediatrics Spec. MD. Galip Erdem Liv Hospital Ankara Spec. MD. Galip Erdem Pediatrics Spec. MD. Hafsa Uçur Liv Hospital Ankara Spec. MD. Hafsa Uçur Pediatric Health and Diseases Spec. MD. Hidayet Katipoğlu Liv Hospital Ankara Spec. MD. Hidayet Katipoğlu Pediatric Health and Diseases Spec. MD. Hüsniye Altan Liv Hospital Ankara Spec. MD. Hüsniye Altan Pediatrics Spec. MD. Mustafa Yücel Kızıltan Liv Hospital Ankara Spec. MD. Mustafa Yücel Kızıltan Pediatrics Spec. MD.  Seral Navdar Liv Hospital Gaziantep Spec. MD. Seral Navdar Pediatric Health and Diseases Spec. MD. Gül Balyemez Liv Hospital Gaziantep Spec. MD. Gül Balyemez Pediatric Health and Diseases Spec. MD. Hasan Avşar Liv Hospital Gaziantep Spec. MD. Hasan Avşar Neonatology Spec. MD. Mert Çakır Liv Hospital Gaziantep Spec. MD. Mert Çakır Pediatrics Spec. MD. Saltuk Buğra Böke Liv Hospital Gaziantep Spec. MD. Saltuk Buğra Böke Pediatric Health and Diseases Spec. MD. Özlem Karaoğlu Liv Hospital Gaziantep Spec. MD. Özlem Karaoğlu Pediatric Health and Diseases Spec. MD. İsmail Ersan Can Liv Hospital Gaziantep Spec. MD. İsmail Ersan Can Pediatric Health and Diseases Spec. MD. Şekibe Zehra Doğan Liv Hospital Gaziantep Spec. MD. Şekibe Zehra Doğan Pediatric Health and Diseases Spec. MD. Gülsenem Sarı Aracı Liv Hospital Samsun Spec. MD. Gülsenem Sarı Aracı Pediatric Health and Diseases Spec. MD. Nazlı Karakullukcu Çebi Liv Hospital Samsun Spec. MD. Nazlı Karakullukcu Çebi Pediatrics Spec. MD. Nezih Akgün Liv Hospital Samsun Spec. MD. Nezih Akgün Pediatric Health and Diseases Spec. MD. Pelin Aytaç Uras Liv Hospital Samsun Spec. MD. Pelin Aytaç Uras Pediatrics MD. VEFA İSAYEVA Liv Bona Dea Hospital Bakü MD. VEFA İSAYEVA Pediatric Health and Diseases Spec. MD.  Elnur Hüseynov Liv Bona Dea Hospital Bakü Spec. MD. Elnur Hüseynov Pediatrics Spec. MD. INARE ELDAROVA Liv Bona Dea Hospital Bakü Spec. MD. INARE ELDAROVA Pediatrics Spec. MD. SADİQ İSMAYILOV Liv Bona Dea Hospital Bakü Spec. MD. SADİQ İSMAYILOV Pediatric Health and Diseases MD. Dr. Elnur Hüseynov MD. Dr. Elnur Hüseynov Pediatrics Spec. MD. Doğa Sevinçok Spec. MD. Doğa Sevinçok Pediatric and Adolescent Psychiatry Spec. MD. Sadık İsmayılov Pediatrics Spec. MD. Melike Akar Liv Hospital Bahçeşehir + Liv Hospital Topkapı Spec. MD. Melike Akar Pediatrics
Trusted Worldwide
30
Years of
Experience
30 Years Badge
Health Türkiye Accreditation

Trusted Worldwide

30 Years of Experience

Patient Reviews
Reviews from 9,651
4,9
Was this content helpful?
Your feedback helps us improve.
What did you like?
Share more details about your experience.
You must give consent to continue.

Thank you!

Your feedback has been submitted successfully. Your input is valuable in helping us improve.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Muhammet Ali Varkal Pediatrics

Assoc. Prof. MD. Muhammet Ali Varkal

Liv Hospital Ulus
Spec. MD. Gizem Güvener Pediatrics

Spec. MD. Gizem Güvener

Liv Hospital Ulus
Spec. MD. Osman Karlı Pediatrics

Spec. MD. Osman Karlı

Liv Hospital Ulus
Spec. MD. Tamer Ünver Neonatal Intensive Care Unit (NICU)

Spec. MD. Tamer Ünver

Liv Hospital Ulus
Assoc. Prof. MD. Adem Dursun Pediatrics

Assoc. Prof. MD. Adem Dursun

Liv Hospital Vadistanbul
Psyc. Selenay Yücel Keleş Pediatric Psychology

Psyc. Selenay Yücel Keleş

Liv Hospital Vadistanbul
Spec. MD.  Fatih Aydın Pediatrics

Spec. MD. Fatih Aydın

Liv Hospital Vadistanbul
Spec. MD. Dicle Çelik Pediatrics

Spec. MD. Dicle Çelik

Liv Hospital Vadistanbul
Spec. MD. Elif Erdem Özcan Pediatrics

Spec. MD. Elif Erdem Özcan

Liv Hospital Vadistanbul
Spec. MD. Hilal Kızıldağ Pediatrics

Spec. MD. Hilal Kızıldağ

Liv Hospital Vadistanbul
Spec. MD. Mehmet Kılıç Pediatrics

Spec. MD. Mehmet Kılıç

Liv Hospital Vadistanbul
Spec. MD. Ozan Uzunhan Neonatology

Spec. MD. Ozan Uzunhan

Liv Hospital Vadistanbul
Spec. MD. Selami Bayrakdar Pediatrics

Spec. MD. Selami Bayrakdar

Liv Hospital Vadistanbul
Spec. MD. Semra Akkuş Akman Pediatrics

Spec. MD. Semra Akkuş Akman

Liv Hospital Vadistanbul
Asst. Prof. MD. Doruk Gül Pediatric Health and Diseases

Asst. Prof. MD. Doruk Gül

Liv Hospital Bahçeşehir
Prof. MD. Murat Sütçü Pediatric Health and Diseases

Prof. MD. Murat Sütçü

Liv Hospital Bahçeşehir
Prof. MD. Nihat Demir Pediatrics

Prof. MD. Nihat Demir

Liv Hospital Bahçeşehir
Psyc. (Psychologist) Buse Yağmur Pediatric Psychology

Psyc. (Psychologist) Buse Yağmur

Liv Hospital Bahçeşehir
Spec. MD. Dilek Hatipoğlu Pediatric Health and Diseases

Spec. MD. Dilek Hatipoğlu

Liv Hospital Bahçeşehir
Spec. MD. Duygu Amine Garavi Pediatrics

Spec. MD. Duygu Amine Garavi

Liv Hospital Bahçeşehir
Spec. MD. Fatih Kaya Pediatric Health and Diseases

Spec. MD. Fatih Kaya

Liv Hospital Bahçeşehir
Spec. MD. Günel Nüsretzade Elmar Pediatrics

Spec. MD. Günel Nüsretzade Elmar

Liv Hospital Bahçeşehir
Spec. MD. Melike Akar Pediatrics

Spec. MD. Melike Akar

Liv Hospital Bahçeşehir
Liv Hospital Topkapı
Spec. MD. Mey Talip Pediatric Intensive Care

Spec. MD. Mey Talip

Liv Hospital Bahçeşehir
Spec. MD. Negın Nahanmoghaddam Pediatrics

Spec. MD. Negın Nahanmoghaddam

Liv Hospital Bahçeşehir
Spec. MD. Nushaba Abdullayeva Pediatric Health and Diseases

Spec. MD. Nushaba Abdullayeva

Liv Hospital Bahçeşehir
Spec. MD. Refika İlbakan Hanımeli Pediatrics

Spec. MD. Refika İlbakan Hanımeli

Liv Hospital Bahçeşehir
Spec. MD. Selman Alazab Pediatrics

Spec. MD. Selman Alazab

Liv Hospital Bahçeşehir
Spec. MD. Özden Durmuş Gönültaş Pediatrics

Spec. MD. Özden Durmuş Gönültaş

Liv Hospital Bahçeşehir
Spec. Md. Öznur Ceylan Pediatric Health and Diseases

Spec. Md. Öznur Ceylan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Aslan Yılmaz Neonatology

Assoc. Prof. MD. Aslan Yılmaz

Liv Hospital Topkapı
Prof. MD. Alpay Çakmak Pediatrics

Prof. MD. Alpay Çakmak

Liv Hospital Topkapı
Spec. MD. Demet Deniz Bilgin Pediatrics

Spec. MD. Demet Deniz Bilgin

Liv Hospital Topkapı
Spec. MD. Nesrin Köseoğlu Pediatric and Adolescent Psychiatry

Spec. MD. Nesrin Köseoğlu

Liv Hospital Topkapı
Spec. MD. Seçil Sözen Pediatrics

Spec. MD. Seçil Sözen

Liv Hospital Topkapı
Spec. MD. Özge Akça Pediatrics

Spec. MD. Özge Akça

Liv Hospital Topkapı
Spec. MD. Şeyma Öz Pediatrics

Spec. MD. Şeyma Öz

Liv Hospital Topkapı
Asst. Prof. MD. Pakize Elif Alkış Pediatrics

Asst. Prof. MD. Pakize Elif Alkış

Liv Hospital Ankara
Prof. MD. Musa Kazım Çağlar Pediatrics

Prof. MD. Musa Kazım Çağlar

Liv Hospital Ankara
Prof. MD. İbrahim Hakan Bucak Pediatrics

Prof. MD. İbrahim Hakan Bucak

Liv Hospital Ankara
Prof.MD. Sevgi Başkan Pediatrics

Prof.MD. Sevgi Başkan

Liv Hospital Ankara
Spec. MD. Büşra Süzen Celbek Pediatrics

Spec. MD. Büşra Süzen Celbek

Liv Hospital Ankara
Spec. MD. Galip Erdem Pediatrics

Spec. MD. Galip Erdem

Liv Hospital Ankara
Spec. MD. Hafsa Uçur Pediatric Health and Diseases

Spec. MD. Hafsa Uçur

Liv Hospital Ankara
Spec. MD. Hidayet Katipoğlu Pediatric Health and Diseases

Spec. MD. Hidayet Katipoğlu

Liv Hospital Ankara
Spec. MD. Hüsniye Altan Pediatrics

Spec. MD. Hüsniye Altan

Liv Hospital Ankara
Spec. MD. Mustafa Yücel Kızıltan Pediatrics

Spec. MD. Mustafa Yücel Kızıltan

Liv Hospital Ankara
Spec. MD.  Seral Navdar Pediatric Health and Diseases

Spec. MD. Seral Navdar

Liv Hospital Gaziantep
Spec. MD. Gül Balyemez Pediatric Health and Diseases

Spec. MD. Gül Balyemez

Liv Hospital Gaziantep
Spec. MD. Hasan Avşar Neonatology

Spec. MD. Hasan Avşar

Liv Hospital Gaziantep
Spec. MD. Mert Çakır Pediatrics

Spec. MD. Mert Çakır

Liv Hospital Gaziantep
Spec. MD. Saltuk Buğra Böke Pediatric Health and Diseases

Spec. MD. Saltuk Buğra Böke

Liv Hospital Gaziantep
Spec. MD. Özlem Karaoğlu Pediatric Health and Diseases

Spec. MD. Özlem Karaoğlu

Liv Hospital Gaziantep
Spec. MD. İsmail Ersan Can Pediatric Health and Diseases

Spec. MD. İsmail Ersan Can

Liv Hospital Gaziantep
Spec. MD. Şekibe Zehra Doğan Pediatric Health and Diseases

Spec. MD. Şekibe Zehra Doğan

Liv Hospital Gaziantep
Spec. MD. Gülsenem Sarı Aracı Pediatric Health and Diseases

Spec. MD. Gülsenem Sarı Aracı

Liv Hospital Samsun
Spec. MD. Nazlı Karakullukcu Çebi Pediatrics

Spec. MD. Nazlı Karakullukcu Çebi

Liv Hospital Samsun
Spec. MD. Nezih Akgün Pediatric Health and Diseases

Spec. MD. Nezih Akgün

Liv Hospital Samsun
Spec. MD. Pelin Aytaç Uras Pediatrics

Spec. MD. Pelin Aytaç Uras

Liv Hospital Samsun
MD. VEFA İSAYEVA Pediatric Health and Diseases

MD. VEFA İSAYEVA

Liv Bona Dea Hospital Bakü
Spec. MD.  Elnur Hüseynov Pediatrics

Spec. MD. Elnur Hüseynov

Liv Bona Dea Hospital Bakü
Spec. MD. INARE ELDAROVA Pediatrics

Spec. MD. INARE ELDAROVA

Liv Bona Dea Hospital Bakü
Spec. MD. SADİQ İSMAYILOV Pediatric Health and Diseases

Spec. MD. SADİQ İSMAYILOV

Liv Bona Dea Hospital Bakü
MD. Dr. Elnur Hüseynov Pediatrics

MD. Dr. Elnur Hüseynov

Spec. MD. Doğa Sevinçok Pediatric and Adolescent Psychiatry

Spec. MD. Doğa Sevinçok

Pediatrics

Spec. MD. Sadık İsmayılov

Related Videos

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 28 17